Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

DNA Methylation and Progression from Early Stage Chronic Lymphocytic Leukemia

FY 2021-22

Summary
Monoclonal B-cell lymphocytosis (MBL) is a pre-condition of chronic lymphocytic leukemia (CLL), which is associated with weakened immunity and greater vulnerability to infections and cancer development. It remains unknown why some individuals with MBL progress to CLL while others do not. Older biological age and changes in DNA methylation (DNAm), one of the biological processes that control gene expression, may be involved. Here, we will measure the methylation levels of DNA isolated from people with MBL who progress to CLL (progressors) compared with those who do not (non-progressors). We will use established tools to determine the epigenetic ages of both groups and statistical modeling to identify the differences in DNAm between the two groups and use those to predict progression. We expect that progressors will be epigenetically older than non-progressors, and we also expect to find the DNAm sites that are crucial in predicting MBL progression. The results of this project will further our understanding of epigenetic contributions to the progression of MBL to CLL. The results may also provide the rationale for exploring new treatments that target abnormal DNA methylation in early-stage CLL patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466783
Name
Fauni Maria Shenna
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
DNA Methylation and Progression from Early Stage Chronic Lymphocytic Leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarker; Cancer Progression; Chronic Lymphocytic Leukemia; Diagnostic Tool; Dna Methylation; Epigenetic Age; Epigenome-Wide Association Studies; Monoclonal B-Cell Lymphocytosis; Statistical Modelling
Abstract
Monoclonal B-cell lymphocytosis (MBL) is a pre-condition of chronic lymphocytic leukemia (CLL), which is associated with weakened immunity and greater vulnerability to infections and cancer development. It remains unknown why some individuals with MBL progress to CLL while others do not. Older biological age and changes in DNA methylation (DNAm), one of the biological processes that control gene expression, may be involved. Here, we will measure the methylation levels of DNA isolated from people with MBL who progress to CLL (progressors) compared with those who do not (non-progressors). We will use established tools to determine the epigenetic ages of both groups and statistical modeling to identify the differences in DNAm between the two groups and use those to predict progression. We expect that progressors will be epigenetically older than non-progressors, and we also expect to find the DNAm sites that are crucial in predicting MBL progression. The results of this project will further our understanding of epigenetic contributions to the progression of MBL to CLL. The results may also provide the rationale for exploring new treatments that target abnormal DNA methylation in early-stage CLL patients.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fauni, Maria Shenna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~
University of Manitoba - $17,500 Grant (2021-22) | Canada Spends